Abstract
The incidence of cutaneous melanoma continues to increase rapidly worldwide. In the United States alone, the incidence of melanoma has been roughly doubling each decade, and according to the most recent projections by the American Cancer Society and the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER), it was estimated that 1 in 41 Americans would develop melanoma in their lifetime. In 2009, 68,720 new cases of melanoma were diagnosed, with 8,650 deaths attributable to the disease [1].
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249
Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr et al (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970–974
Goldstein AM, Tucker MA (1995) Genetic epidemiology of familial melanoma. Dermatol Clin 13:605–612
Goldstein AM, Tucker MA (2001) Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol 137:1493–1496
Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC (1985) High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 102:458–465
Lynch HT, Fusaro RM, Lynch J (1995) Hereditary cancer in adults. Cancer Detect Prev 19:219–233
Norris W (1820) Case of Fungoid Disease. Edinb Med Surg J 16:562–565
Norris W (1857) Eight cases of melanosis with pathological and therapeautical remarks on that disease, vol 1. Longman, Brown, Green, Longmans, and Roberts, London
Cawley EP, Kruse WT, Pinkus HK (1952) Genetic aspects of malignant melanoma. AMA Arch Derm Syphilol 65:440–450
Frichot BC 3rd, Lynch HT, Guirgis HA, Harris RE, Lynch JF (1977) New cutaneous phenotype in familial malignant melanoma. Lancet 1:864–865
Clark WH Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ (1978) Origin of familial malignant melanomas from heritable melanocytic lesions. ’The B-K mole syndrome’. Arch Dermatol 114:732–738
Lynch HT, Frichot BC 3rd, Lynch JF (1978) Familial atypical multiple mole-melanoma syndrome. J Med Genet 15:352–356
Clark WH Jr (1988) The dysplastic nevus syndrome. Arch Dermatol 124:1207–1210
Kopf AW, Friedman RJ, Rigel DS (1990) Atypical mole syndrome. J Am Acad Dermatol 22:117–118
NIH Consensus Development Conference Panel on Early Melanoma (1992) Diagnosis and treatment of early melanoma. In: Consens Statement, January 27–29, 1992, 1–25
Ackerman AB (1988) What naevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma? A riddle and an answer. Histopathology 13:241–256
Clark WH Jr, Elder DE, Guerry D, Epstein MN, Greene MH, Van Horn M (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15:1147–1165
Duray PH, Ernstoff MS (1987) Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Clinicopathologic experience in a 100-bed hospital. Arch Dermatol 123:80–84
Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Guerry D, Witmer WK, Thompson J, Matozzo I, Fraser MC (1985) Acquired precursors of cutaneous melanoma The familial dysplastic nevus syndrome. N Engl J Med 312:91–97
Greene MH, Fraser MC, Clark WH Jr, Elder DE, Guerry D, Kraemer KH (1984) For the record: the history of precursors to malignant melanoma. Arch Dermatol 120:18–21
Rhodes AR, Harrist TJ, Day CL, Mihm MC Jr, Fitzpatrick TB, Sober AJ (1983) Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol 9:563–574
Rivers JK, Kopf AW, Vinokur AF, Rigel DS, Friedman RJ, Heilman ER, Levenstein M (1990) Clinical characteristics of malignant melanomas developing in persons with dysplastic nevi. Cancer 65:1232–1236
Skender-Kalnenas TM, English DR, Heenan PJ (1995) Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol 33:1000–1007
Greene MH (1999) The genetics of hereditary melanoma and nevi. 1998 update. Cancer 86:2464–2477
Halpern AC, Guerry D, Elder DE, Clark WH Jr, Synnestvedt M, Norman S, Ayerle R (1991) Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 127:995–999
Holly EA, Kelly JW, Shpall SN, Chiu SH (1987) Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 17:459–468
Rigel DS, Rivers JK, Kopf AW, Friedman RJ, Vinokur AF, Heilman ER, Levenstein M (1989) Dysplastic nevi. Markers for increased risk for melanoma. Cancer 63:386–389
Roush GC, Nordlund JJ, Forget B, Gruber SB, Kirkwood JM (1988) Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med 17:273–279
Slade J, Marghoob AA, Salopek TG, Rigel DS, Kopf AW, Bart RS (1995) Atypical mole syndrome: risk factor for cutaneous melanoma and implications for management. J Am Acad Dermatol 32:479–494
Swerdlow AJ, English J, MacKie RM, O’Doherty CJ, Hunter JA, Clark J (1984) Benign naevi associated with high risk of melanoma. Lancet 2:168
Swerdlow AJ, English J, MacKie RM, O’Doherty CJ, Hunter JA, Clark J, Hole DJ (1986) Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) 292: 1555–1559
Titus-Ernstoff L, Duray PH, Ernstoff MS, Barnhill RL, Horn PL, Kirkwood JM (1988) Dysplastic nevi in association with multiple primary melanoma. Cancer Res 48:1016–1018
Tsao H, Sober AJ, Niendorf KB, Zembowicz A (2004) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 7-2004. A 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma. N Engl J Med 350:924–932
Annessi G, Cattaruzza MS, Abeni D, Baliva G, Laurenza M, Macchini V, Melchi F, Ruatti P, Puddu P, Faraggiana T (2001) Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi. J Am Acad Dermatol 45:77–85
Barnhill RL (1991) Current status of the dysplastic melanocytic nevus. J Cutan Pathol 18:147–159
Barnhill RL (2004) Pathology of melanocytic nevi and malignant melanoma. Springer, New York
Barnhill RL, Roush GC, Ernstoff MS, Kirkwood JM (1992) Interclinician agreement on the recognition of selected gross morphologic features of pigmented lesions. Studies of melanocytic nevi V. J Am Acad Dermatol 26:185–190
Grob JJ, Andrac L, Romano MH, Davin D, Collet-Villette AM, Munoz MH, Bonerandi JJ (1988) Dysplastic naevus in non-familial melanoma. A clinicopathological study of 101 cases. Br J Dermatol 118:745–752
Meyer LJ, Piepkorn M, Goldgar DE, Lewis CM, Cannon-Albright LA, Zone JJ, Skolnick MH (1996) Interobserver concordance in discriminating clinical atypia of melanocytic nevi, and correlations with histologic atypia. J Am Acad Dermatol 34:618–625
Tripp JM, Kopf AW, Marghoob AA, Bart RS (2002) Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology. J Am Acad Dermatol 46:674–682
Williams ML, Sagebiel RW (1994) Melanoma risk factors and atypical moles. West J Med 160:343–350
Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA et al (2005) Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 23:7168–7177
Platz A, Ringborg U, Hansson J (2000) Hereditary cutaneous melanoma. Semin Cancer Biol 10:319–326
de Snoo FA, Kroon MW, Bergman W, ter Huurne JA, Houwing-Duistermaat JJ, van Mourik L, Snels DG, Breuning MH, Willemze R, Frants RR et al (2007) From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients. J Am Acad Dermatol 56:748–752
Kraemer KH, Greene MH, Tarone R, Elder DE, Clark WH Jr, Guerry D (1983) Dysplastic naevi and cutaneous melanoma risk. Lancet 2:1076–1077
Kraemer KH, Tucker M, Tarone R, Elder DE, Clark WH Jr (1986) Risk of cutaneous melanoma in dysplastic nevus syndrome types A and B. N Engl J Med 315:1615–1616
Garbe C, Buttner P, Weiss J, Soyer HP, Stocker U, Kruger S, Roser M, Weckbecker J, Panizzon R, Bahmer F et al (1994) Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 102:695–699
Garbe C, Kruger S, Stadler R, Guggenmoos-Holzmann I, Orfanos CE (1989) Markers and relative risk in a German population for developing malignant melanoma. Int J Dermatol 28:517–523
Grob JJ, Gouvernet J, Aymar D, Mostaque A, Romano MH, Collet AM, Noe MC, Diconstanzo MP, Bonerandi JJ (1990) Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 66:387–395
Slade J, Salopek TG, Marghoob AA, Kopf AW, Rigel DS (1995) Risk of developing cutaneous melanoma in atypical-mole syndrome: New York University experience and literature review. Recent Results Cancer Res 139:87–104
Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, Guerry D, Clark WH Jr (1997) Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 277:1439–1444
Armstrong BK, de Klerk NH, Holman CD (1986) Etiology of common acquired melanocytic nevi: constitutional variables, sun exposure, and diet. J Natl Cancer Inst 77:329–335
Piepkorn MW (1994) Genetic basis of susceptibility to melanoma. J Am Acad Dermatol 31:1022–1039
Goldgar DE, Cannon-Albright LA, Meyer LJ, Piepkorn MW, Zone JJ, Skolnick MH (1991) Inheritance of nevus number and size in melanoma and dysplastic nevus syndrome kindreds. J Natl Cancer Inst 83:1726–1733
Goldgar DE, Cannon-Albright LA, Meyer LJ, Piepkorn MW, Zone JJ, Skolnick MH (1992) Inheritance of nevus number and size in melanoma/DNS kindreds. Cytogenet Cell Genet 59:200–202
Meyer LJ, Goldgar DE, Cannon-Albright LA, Piepkorn MW, Zone JJ, Risman MB, Skolnick MH (1992) Number, size, and histopathology of nevi in Utah kindreds. Cytogenet Cell Genet 59:167–169
Cannon-Albright LA, Kamb A, Skolnick M (1996) A review of inherited predisposition to melanoma. Semin Oncol 23:667–672
Dracopoli NC, Houghton AN, Old LJ (1985) Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proc Natl Acad Sci U S A 82:1470–1474
Nancarrow DJ, Mann GJ, Holland EA, Walker GJ, Beaton SC, Walters MK, Luxford C, Palmer JM, Donald JA, Weber JL et al (1993) Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 53:936–942
MacGeoch C, Bishop JA, Bataille V, Bishop DT, Frischauf AM, Meloni R, Cuzick J, Pinney E, Spurr NK (1994) Genetic hetero-geneity in familial malignant melanoma. Hum Mol Genet 3:2195–2200
Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE et al (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258:1148–1152
Gruis NA, Sandkuijl LA, Weber JL, van der Zee A, Borgstein AM, Bergman W, Frants RR (1993) Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res 3:271–277
Cannon-Albright LA, Meyer LJ, Goldgar DE, Lewis CM, McWhorter WP, Jost M, Harrison D, Anderson DE, Zone JJ, Skolnick MH (1994) Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 54:6041–6044
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440
Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J et al (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23–26
Meyer LJ, Zone JH (1994) Genetics of cutaneous melanoma. J Invest Dermatol 103:112S–116S
Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nat Genet 8:15–21
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753–756
Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707
Motokura T, Arnold A (1993) Cyclin D and oncogenesis. Curr Opin Genet Dev 3:5–10
Nigg EA (1993) Targets of cyclin-dependent protein kinases. Curr Opin Cell Biol 5:187–193
Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L (2003) Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 22:5055–5059
Sherr CJ (1993) Mammalian G1 cyclins. Cell 73:1059–1065
Solomon MJ (1993) Activation of the various cyclin/cdc2 protein kinases. Curr Opin Cell Biol 5:180–186
Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM (1993) Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487–497
Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, Leachman SA (2006) Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol 126:660–666
Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W et al (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99–106
Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R et al (2005) Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 97:1507–1515
Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N (1999) CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 91:446–452
Auroy S, Avril MF, Chompret A, Pham D, Goldstein AM, Bianchi-Scarra G, Frebourg T, Joly P, Spatz A, Rubino C et al (2001) Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 32:195–202
Blackwood MA, Holmes R, Synnestvedt M, Young M, George C, Yang H, Elder DE, Schuchter LM, Guerry D, Ganguly A (2002) Multiple primary melanoma revisited. Cancer 94:2248–2255
Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J (2000) CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 60:6864–6867
Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, Langmark F, Loeb M, Akslen LA, Molven A et al (2008) Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 47:175–184
Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ (1998) CDKN2A mutations in multiple primary melanomas. N Engl J Med 338:879–887
Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, Azon A, Gonzalez U, Castel T, Campoy A et al (2005) Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 23:3043–3051
Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA, Mujumdar U, Canchola R, Armstrong BK, Kricker A et al (2007) CDKN2A germline mutations in individuals with cutaneous melanoma. J Invest Dermatol 127:1234–1243
Harland M, Taylor CF, Chambers PA, Kukalizch K, Randerson-Moor JA, Gruis NA, de Snoo FA, ter Huurne JA, Goldstein AM, Tucker MA et al (2005) A mutation hotspot at the p14ARF splice site. Oncogene 24:4604–4608
Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B (1998) Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7:209–216
Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97–99
Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR (1995) CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 5:169–177
Borg A, Johannsson U, Johannsson O, Hakansson S, Westerdahl J, Masback A, Olsson H, Ingvar C (1996) Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 56:2497–2500
Hashemi J, Bendahl PO, Sandberg T, Platz A, Linder S, Stierner U, Olsson H, Ingvar C, Hansson J, Borg A (2001) Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families. Genes Chromosomes Cancer 31:107–116
Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J et al (1997) Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:2061–2067
Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D (1999) Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128–132
MacKie RM, Andrew N, Lanyon WG, Connor JM (1998) CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 111:269–272
Mistry SH, Taylor C, Randerson-Moor JA, Harland M, Turner F, Barrett JH, Whitaker L, Jenkins RB, Knowles MA, Bishop JA et al (2005) Prevalence of 9p21 deletions in UK melanoma families. Genes Chromosomes Cancer 44:292–300
Peric B, Cerkovnik P, Novakovic S, Zgajnar J, Besic N, Hocevar M (2008) Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families. BMC Med Genet 9:86
Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R et al (1998) Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat 11:424–431
Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL, Tucker MA, Bianchi-Scarra G, Bressac-de Paillerets B, Goldstein AM (2000) A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 67:311–319
Yakobson E, Shemesh P, Azizi E, Winkler E, Lassam N, Hogg D, Brookes S, Peters G, Lotem M, Zlotogorski A et al (2000) Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Eur J Hum Genet 8:590–596
Yakobson EA, Zlotogorski A, Shafir R, Cohen M, Icekson M, Landau M, Brenner S, Usher S, Peretz H (1998) Screening for tumour suppressor p16(CDKN2A) germline mutations in Israeli melanoma families. Clin Chem Lab Med 36:645–648
Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J et al (2002) Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94:894–903
Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW (1995) Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 4:1845–1852
Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK (2001) MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69:765–773
Hoiom V, Tuominen R, Kaller M, Linden D, Ahmadian A, Mansson-Brahme E, Egyhazi S, Sjoberg K, Lundeberg J, Hansson J (2009) MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters. Pigment Cell Melanoma Res 22:196–204
Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN (2001) Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 117:294–300
Palmer JS, Duffy DL, Box NF, Aitken JF, O’Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA (2000) Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 66:176–186
Blanchard SG, Harris CO, Ittoop OR, Nichols JS, Parks DJ, Truesdale AT, Wilkison WO (1995) Agouti antagonism of melanocortin binding and action in the B16F10 murine melanoma cell line. Biochemistry 34:10406–10411
Voisey J, Kelly G, Van Daal A (2003) Agouti signal protein regulation in human melanoma cells. Pigment Cell Res 16:65–71
Rouzaud F, Kadekaro AL, Abdel-Malek ZA, Hearing VJ (2005) MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res 571:133–152
Box NF, Wyeth JR, O’Gorman LE, Martin NG, Sturm RA (1997) Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 6:1891–1897
Valverde P, Healy E, Jackson I, Rees JL, Thody AJ (1995) Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 11:328–330
Goldstein AM, Chidambaram A, Halpern A, Holly EA, Guerry ID, Sagebiel R, Elder DE, Tucker MA (2002) Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res 12:51–55
Gillanders E, Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, Sood R, Park N, Faruque M, Markey C et al (2003) Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 73:301–313
Brown KM, Macgregor S, Montgomery GW, Craig DW, Zhao ZZ, Iyadurai K, Henders AK, Homer N, Campbell MJ, Stark M et al (2008) Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 40:838–840
Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA (2000) Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 92:1006–1010
Shennan MG, Badin AC, Walsh S, Summers A, From L, McKenzie M, Goldstein AM, Tucker MA, Hogg D, Lassam N (2000) Lack of germline CDK6 mutations in familial melanoma. Oncogene 19:1849–1852
Walker GJ, Indsto JO, Sood R, Faruque MU, Hu P, Pollock PM, Duray P, Holland EA, Brown K, Kefford RF et al (2004) Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval. Genes Chromosomes Cancer 41:56–64
Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, Shellman YG, Robinson WA (2008) MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 68:1362–1368
Jonsson G, Bendahl PO, Sandberg T, Kurbasic A, Staaf J, Sunde L, Cruger DG, Ingvar C, Olsson H, Borg A (2005) Mapping of a novel ocular and cutaneous melanoma susceptibility locus to chromosome 9q21.32. J Natl Cancer Inst 97:1377–1382
Bergman W, Gruis N (1996) Familial melanoma and pancreatic cancer. N Engl J Med 334:471–472
Bergman W, Watson P, de Jong J, Lynch HT, Fusaro RM (1990) Systemic cancer and the FAMMM syndrome. Br J Cancer 61:932–936
Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92:1260–1266
Goldstein AM (2004) Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 23:630
Hruban RH, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Falatko F, Yeo CJ, Kern SE (1999) Familial pancreatic cancer. Ann Oncol 10(Suppl 4):69–73
Landi S (2009) Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat Res 681:299–307
Lynch HT, Fusaro RM (1991) Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 6:127–131
Parker JF, Florell SR, Alexander A, DiSario JA, Shami PJ, Leachman SA (2003) Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol 139:1019–1025
Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87:809–811
Lynch HT, Krush AJ (1968) Heredity and malignant melanoma: implications for early cancer detection. Can Med Assoc J 99:17–21
Whelan AJ, Bartsch D, Goodfellow PJ (1995) Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333:975–977
Mantelli M, Barile M, Ciotti P, Ghiorzo P, Lantieri F, Pastorino L, Catricala C, Torre GD, Folco U, Grammatico P et al (2002) High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 107:214–221
Mantelli M, Pastorino L, Ghiorzo P, Barile M, Bruno W, Gargiulo S, Sormani MP, Gliori S, Vecchio S, Ciotti P et al (2004) Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. Melanoma Res 14:443–448
Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B et al (2006) High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66:9818–9828
Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grutzmann R, Colombo-Benkmann M, Ziegler A et al (2002) CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236:730–737
Lynch HT, Brand RE, Hogg D, Deters CA, Fusaro RM, Lynch JF, Liu L, Knezetic J, Lassam NJ, Goggins M et al (2002) Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94:84–96
Ciotti P, Strigini P, Bianchi-Scarra G (1996) Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group. N Engl J Med 334:469–470; author reply 471–462
Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainero ML, Ferrari C, Santi PL, De Marchi R, Farris A et al (1999) Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 83:441–448
Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, Redston M, Gallinger S (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60:409–416
Lal G, Liu L, Hogg D, Lassam NJ, Redston MS, Gallinger S (2000) Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer 27:358–361
Moskaluk CA, Hruban H, Lietman A, Smyrk T, Fusaro L, Fusaro R, Lynch J, Yeo CJ, Jackson CE, Lynch HT et al (1998) Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no. 148. Online. Hum Mutat 12:70
Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP et al (1998) Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 58:2298–2303
Hewitt C, Lee Wu C, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N (2002) Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 11:1273–1279
Petronzelli F, Sollima D, Coppola G, Martini-Neri ME, Neri G, Genuardi M (2001) CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. Genes Chromosomes Cancer 31:398–401
Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Bishop JN et al (2001) A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10:55–62
Rizos H, Puig S, Badenas C, Malvehy J, Darmanian AP, Jimenez L, Mila M, Kefford RF (2001) A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 20:5543–5547
Bataille V, Pinney E, Hungerford JL, Cuzick J, Bishop DT, Newton JA (1993) Five cases of coexistent primary ocular and cutaneous melanoma. Arch Dermatol 129:198–201
Bellet RE, Shields JA, Soll DB, Bernardino EA (1980) Primary choroidal and cutaneous melanomas occurring in a patient with the B-K mole syndrome phenotype. Am J Ophthalmol 89:567–570
Greene MH, Sanders RJ, Chu FC, Clark WH Jr, Elder DE, Cogan DG (1983) The familial occurrence of cutaneous melanoma, intraocular melanoma, and the dysplastic nevus syndrome. Am J Ophthalmol 96:238–245
Hurst EA, Harbour JW, Cornelius LA (2003) Ocular melanoma: a review and the relationship to cutaneous melanoma. Arch Dermatol 139:1067–1073
Richtig E, Langmann G, Mullner K, Smolle J (2004) Ocular melanoma: epidemiology, clinical presentation and relationship with dysplastic nevi. Ophthalmologica 218:111–114
Rodriguez-Sains RS (1986) Ocular findings in patients with dysplastic nevus syndrome. Ophthalmology 93:661–665
Singh AD, Shields CL, Shields JA, Eagle RC, De Potter P (1995) Uveal melanoma and familial atypical mole and melanoma (FAM-M) syndrome. Ophthalmic Genet 16:53–61
Singh AD, Shields JA, Eagle RC, Shields CL, Marmor M, De Potter P (1994) Iris melanoma in a ten-year-old boy with familial atypical mole-melanoma (FAM-M) syndrome. Ophthalmic Genet 15:145–149
Smith JH, Padnick-Silver L, Newlin A, Rhodes K, Rubinstein WS (2007) Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi. Ophthalmology 114:774–779
Vajdic CM, Kricker A, Giblin M, McKenzie J, Aitken J, Giles GG, Armstrong BK (2001) Eye color and cutaneous nevi predict risk of ocular melanoma in Australia. Int J Cancer 92:906–912
van Hees CL, Jager MJ, Bleeker JC, Kemme H, Bergman W (1998) Occurrence of cutaneous and uveal melanoma in patients with uveal melanoma and their first degree relatives. Melanoma Res 8:175–180
Vink J, Crijns MB, Mooy CM, Bergman W, Oosterhuis JA, Went LN (1990) Ocular melanoma in families with dysplastic nevus syndrome. J Am Acad Dermatol 23:858–862
Taylor MR, Guerry D, Bondi EE, Shields JA, Augsburger JJ, Lusk EJ, Elder DE, Clark WH Jr, Van Horn M (1984) Lack of association between intraocular melanoma and cutaneous dysplastic nevi. Am J Ophthalmol 98:478–482
Wang X, Egan KM, Gragoudas ES, Kelsey KT (1996) Constitutional alterations in p16 in patients with uveal melanoma. Melanoma Res 6:405–410
Duffy DL, Box NF, Chen W, Palmer JS, Montgomery GW, James MR, Hayward NK, Martin NG, Sturm RA (2004) Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet 13:447–461
Jannot AS, Meziani R, Bertrand G, Gerard B, Descamps V, Archimbaud A, Picard C, Ollivaud L, Basset-Seguin N, Kerob D et al (2005) Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma. Eur J Hum Genet 13:913–920
Kefford R, Bishop JN, Tucker M, Bressac-de Paillerets B, Bianchi-Scarra G, Bergman W, Goldstein A, Puig S, Mackie R, Elder D et al (2002) Genetic testing for melanoma. Lancet Oncol 3:653–654
Kefford RF, Newton Bishop JA, Bergman W, Tucker MA (1999) Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 17:3245–3251
Niendorf KB, Tsao H (2006) Cutaneous melanoma: family screening and genetic testing. Dermatol Ther 19:1–8
Niendorf KB, Goggins W, Yang G, Tsai KY, Shennan M, Bell DW, Sober AJ, Hogg D, Tsao H (2006) MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet 43:501–506
Wang W, Niendorf KB, Patel D, Blackford A, Marroni F, Sober AJ, Parmigiani G, Tsao H (2010) Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res 70:552–559
Berg P, Wennberg AM, Tuominen R, Sander B, Rozell BL, Platz A, Hansson J (2004) Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res 14:251–255
Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG (2000) Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 136:1118–1122
Holland EA, Schmid H, Kefford RF, Mann GJ (1999) CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 25:339–348
Tsao H, Niendorf K (2004) Genetic testing in hereditary melanoma. J Am Acad Dermatol 51:803–808
Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann GJ (2009) Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med 11:265–278
Mesters I, Jonkman L, Vasen H, de Vries H (2009) Skin self-examination of persons from families with familial atypical multiple mole melanoma (FAMMM). Patient Educ Couns 75:251–255
Bergenmar M, Hansson J, Brandberg Y (2009) Family members’ perceptions of genetic testing for malignant melanoma – a prospective interview study. Eur J Oncol Nurs 13:74–80
Kimmey MB, Bronner MP, Byrd DR, Brentnall TA (2002) Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 56:S82–S86
Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA (2003) Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 57:23–29
Brentnall TA (2000) Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am 84:707–718
Barnhill RL, Hurwitz S, Duray PH, Arons MS (1988) The dysplastic nevus: recognition and management. Plast Reconstr Surg 81:280–289
Crutcher WA (1988) The dysplastic nevus and its clinical management. Adv Dermatol 3:187–203
Sober AJ, Burstein JM (1995) Precursors to skin cancer. Cancer 75:645–650
Bafounta ML, Beauchet A, Aegerter P, Saiag P (2001) Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 137:1343–1350
Carli P, de Giorgi V, Chiarugi A, Nardini P, Weinstock MA, Crocetti E, Stante M, Giannotti B (2004) Addition of dermoscopy to conventional naked-eye examination in melanoma screening: a randomized study. J Am Acad Dermatol 50:683–689
Carli P, De Giorgi V, Crocetti E, Mannone F, Massi D, Chiarugi A, Giannotti B (2004) Improvement of malignant/benign ratio in excised melanocytic lesions in the ‘dermoscopy era’: a retrospective study 1997-2001. Br J Dermatol 150:687–692
Haenssle HA, Vente C, Bertsch HP, Rupprecht R, Abuzahra F, Junghans V, Ellinghaus B, Emmert S, Hallermann C, Rosenberger A et al (2004) Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy. Eur J Cancer Prev 13:133–138
Kittler H, Pehamberger H, Wolff K, Binder M (2000) Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol 43:467–476
Menzies SW, Gutenev A, Avramidis M, Batrac A, McCarthy WH (2001) Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol 137:1583–1589
Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL (1996) Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 88:17–23
U.S. Preventative Services Task Force (2009) Screening for skin cancer: U.S. Preventative Services Task Force recommendation statement. Ann Intern Med 150:188–193
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Chao, E.D., Gabree, M.J., Tsao, H. (2010). Familial Atypical Mole Melanoma (FAMM) Syndrome. In: Chung, D., Haber, D. (eds) Principles of Clinical Cancer Genetics. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-93846-2_10
Download citation
DOI: https://doi.org/10.1007/978-0-387-93846-2_10
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-93844-8
Online ISBN: 978-0-387-93846-2
eBook Packages: MedicineMedicine (R0)